Chemistry World: ‘Lateral flow 4.0 and the next generation of rapid diagnostics’
In this Chemistry World article, Elizabeth Paull (Managing Director of Chelsea Technologies) and Dermott O’Callaghan (Head of Product Development at Stream Bio) discuss the need for new approaches to rapid diagnostics and how Claritas represents a promising solution.
The response to the COVID-19 pandemic highlighted a lack of options for diagnostic testing, with trade-offs between the accuracy promised by lab-based techniques and the accessibility and speed afforded by rapid point-of-care tests. In this article, we discuss how Brightline DX was formed to develop an innovative platform, which addresses these major challenges in the diagnostics market.
By bringing together unique technology from our founding partners, Claritas offers an enhanced approach to conventional lateral flow tests, improving detection sensitivity and aiding detection in samples even from asymptomatic carriers. Designed for use in any environment, the robust, portable platform can provide accurate and reliable results in around ten minutes.
Thanks to the easily adaptable nature of the platform, there is an enormous range of potential applications for Claritas beyond COVID-19 testing. The article outlines some of the exciting areas we are exploring, including an SBRI-funded project currently underway to adapt our technology to rule out heart attacks in ambulances or hospitals, allowing prioritisation of urgent cases. The platform’s potential to enhance testing stretches beyond healthcare, with promising opportunities in areas such as environmental monitoring.
Our article is part of Chemistry World’s ‘Chemistry 4.0’ supplement, exploring exciting innovations that are set to revolutionise the industry. To find out more about our work to develop the next generation of rapid diagnostics, read the full article here.